Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
278 | 3744 | 34.3 | 72% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
429 | 3 | SPHINGOSINE 1 PHOSPHATE//CERAMIDE//SPHINGOLIPIDS | 27734 |
2112 | 2 | PLATELET ACTIVATING FACTOR//LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2//PAF | 5117 |
278 | 1 | PLATELET ACTIVATING FACTOR//PAF//PAF ANTAGONIST | 3744 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PLATELET ACTIVATING FACTOR | authKW | 1290410 | 13% | 32% | 497 |
2 | PAF | authKW | 460950 | 5% | 33% | 171 |
3 | PAF ANTAGONIST | authKW | 453740 | 2% | 64% | 87 |
4 | JOURNAL OF LIPID MEDIATORS | journal | 316740 | 3% | 38% | 103 |
5 | PLATELET ACTIVATING FACTOR PAF | authKW | 199567 | 2% | 39% | 62 |
6 | JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING | journal | 183601 | 2% | 29% | 79 |
7 | PAF RECEPTOR | authKW | 163148 | 1% | 51% | 39 |
8 | PLATELET ACTIVATING FACTOR RECEPTOR | authKW | 140915 | 1% | 52% | 33 |
9 | PAF RECEPTOR ANTAGONIST | authKW | 125253 | 1% | 59% | 26 |
10 | WEB 2086 | authKW | 125253 | 1% | 59% | 26 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 5570 | 24% | 0% | 904 |
2 | Biochemistry & Molecular Biology | 3705 | 29% | 0% | 1081 |
3 | Immunology | 1896 | 12% | 0% | 464 |
4 | Biophysics | 1402 | 8% | 0% | 300 |
5 | Allergy | 1290 | 3% | 0% | 110 |
6 | Cell Biology | 964 | 10% | 0% | 379 |
7 | Respiratory System | 565 | 4% | 0% | 142 |
8 | Hematology | 506 | 4% | 0% | 163 |
9 | Peripheral Vascular Diseases | 476 | 4% | 0% | 152 |
10 | Physiology | 444 | 5% | 0% | 178 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | DEV MED BIOTECHNOL | 48924 | 0% | 100% | 6 |
2 | HB WELLS PEDIAT | 30691 | 0% | 21% | 18 |
3 | CATTEDRA NEFROL IMMUNOPATOL | 16308 | 0% | 100% | 2 |
4 | INSERM U200 | 16308 | 0% | 100% | 2 |
5 | MED 2 DIPARTIMENTO SCI CLIN BIOL | 16308 | 0% | 100% | 2 |
6 | PHARMACOCHIM MOLEC 2 PL JUSSIEU | 16308 | 0% | 100% | 2 |
7 | TSUKUBA S 13 TOKODAI 5 CHOME | 16308 | 0% | 100% | 2 |
8 | PHARMACOCHIM MOLEC | 14675 | 0% | 60% | 3 |
9 | OSWALDO CRUZ FISIOL FARMACODINAM | 10871 | 0% | 67% | 2 |
10 | SHIONOGI SAGISU 5124 FUKUSHIMA KU | 10871 | 0% | 67% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF LIPID MEDIATORS | 316740 | 3% | 38% | 103 |
2 | JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING | 183601 | 2% | 29% | 79 |
3 | AGENTS AND ACTIONS | 14948 | 2% | 2% | 77 |
4 | LIPIDS | 12100 | 3% | 2% | 94 |
5 | PROSTAGLANDINS | 10187 | 1% | 3% | 43 |
6 | PHARMACOLOGICAL RESEARCH COMMUNICATIONS | 5994 | 1% | 3% | 26 |
7 | BRITISH JOURNAL OF PHARMACOLOGY | 5303 | 3% | 1% | 109 |
8 | INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY | 4873 | 1% | 2% | 40 |
9 | ADVANCES IN PROSTAGLANDIN THROMBOXANE AND LEUKOTRIENE RESEARCH | 4499 | 1% | 3% | 21 |
10 | PROSTAGLANDINS & OTHER LIPID MEDIATORS | 3244 | 1% | 1% | 27 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PLATELET ACTIVATING FACTOR | 1290410 | 13% | 32% | 497 | Search PLATELET+ACTIVATING+FACTOR | Search PLATELET+ACTIVATING+FACTOR |
2 | PAF | 460950 | 5% | 33% | 171 | Search PAF | Search PAF |
3 | PAF ANTAGONIST | 453740 | 2% | 64% | 87 | Search PAF+ANTAGONIST | Search PAF+ANTAGONIST |
4 | PLATELET ACTIVATING FACTOR PAF | 199567 | 2% | 39% | 62 | Search PLATELET+ACTIVATING+FACTOR+PAF | Search PLATELET+ACTIVATING+FACTOR+PAF |
5 | PAF RECEPTOR | 163148 | 1% | 51% | 39 | Search PAF+RECEPTOR | Search PAF+RECEPTOR |
6 | PLATELET ACTIVATING FACTOR RECEPTOR | 140915 | 1% | 52% | 33 | Search PLATELET+ACTIVATING+FACTOR+RECEPTOR | Search PLATELET+ACTIVATING+FACTOR+RECEPTOR |
7 | PAF RECEPTOR ANTAGONIST | 125253 | 1% | 59% | 26 | Search PAF+RECEPTOR+ANTAGONIST | Search PAF+RECEPTOR+ANTAGONIST |
8 | WEB 2086 | 125253 | 1% | 59% | 26 | Search WEB+2086 | Search WEB+2086 |
9 | PLATELET ACTIVATING FACTOR ANTAGONIST | 124353 | 1% | 51% | 30 | Search PLATELET+ACTIVATING+FACTOR+ANTAGONIST | Search PLATELET+ACTIVATING+FACTOR+ANTAGONIST |
10 | Y 24180 | 124022 | 0% | 89% | 17 | Search Y+24180 | Search Y+24180 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | MONTRUCCHIO, G , ALLOATTI, G , CAMUSSI, G , (2000) ROLE OF PLATELET-ACTIVATING FACTOR IN CARDIOVASCULAR PATHOPHYSIOLOGY.PHYSIOLOGICAL REVIEWS. VOL. 80. ISSUE 4. P. 1669 -1699 | 300 | 71% | 226 |
2 | BRAQUET, P , TOUQUI, L , SHEN, TY , VARGAFTIG, BB , (1987) PERSPECTIVES IN PLATELET-ACTIVATING-FACTOR RESEARCH.PHARMACOLOGICAL REVIEWS. VOL. 39. ISSUE 2. P. 97-145 | 249 | 75% | 1416 |
3 | OSTERMANN, G , KERTSCHER, HP , HOFMANN, B , (1990) PLATELET-ACTIVATING FACTOR - A BIOLOGICALLY-ACTIVE PHOSPHOLIPID.PHARMAZIE. VOL. 45. ISSUE 7. P. 465-487 | 377 | 84% | 2 |
4 | KOLTAI, M , HOSFORD, D , GUINOT, P , ESANU, A , BRAQUET, P , (1991) PAF A REVIEW OF ITS EFFECTS, ANTAGONISTS AND POSSIBLE FUTURE CLINICAL IMPLICATIONS .2..DRUGS. VOL. 42. ISSUE 2. P. 174 -204 | 225 | 71% | 103 |
5 | HANDLEY, DA , (1990) PRECLINICAL AND CLINICAL-PHARMACOLOGY OF PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS.MEDICINAL RESEARCH REVIEWS. VOL. 10. ISSUE 3. P. 351 -370 | 186 | 95% | 13 |
6 | ISHII, S , SHIMIZU, T , (2000) PLATELET-ACTIVATING FACTOR (PAF) RECEPTOR AND GENETICALLY ENGINEERED PAF RECEPTOR MUTANT MICE.PROGRESS IN LIPID RESEARCH. VOL. 39. ISSUE 1. P. 41 -82 | 179 | 52% | 213 |
7 | CHAO, W , OLSON, MS , (1993) PLATELET-ACTIVATING-FACTOR - RECEPTORS AND SIGNAL-TRANSDUCTION.BIOCHEMICAL JOURNAL. VOL. 292. ISSUE . P. 617-629 | 120 | 71% | 367 |
8 | FEUERSTEIN, G , RABINOVICI, R , LEOR, J , WINKLER, JD , VONHOF, S , (1997) PLATELET-ACTIVATING FACTOR AND CARDIAC DISEASES: THERAPEUTIC POTENTIAL FOR PAF INHIBITORS.JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING. VOL. 15. ISSUE 3. P. 255-284 | 118 | 84% | 21 |
9 | SNYDER, F , (1995) PLATELET-ACTIVATING-FACTOR AND ITS ANALOGS - METABOLIC PATHWAYS AND RELATED INTRACELLULAR PROCESSES.BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM. VOL. 1254. ISSUE 3. P. 231 -249 | 146 | 60% | 151 |
10 | EVANGELOU, AM , (1994) PLATELET-ACTIVATING-FACTOR (PAF) - IMPLICATIONS FOR CORONARY HEART AND VASCULAR DISEASES.PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS. VOL. 50. ISSUE 1. P. 1-28 | 156 | 60% | 84 |
Classes with closest relation at Level 1 |